API | fosmidomycin

fosmidomycin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Fosmidomycin is an antibiotic that was originally isolated from culture broths of bacteria of the genus Streptomyces. It specifically inhibits DXP reductoisomerase, a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. It is a structural analogue of 2-C-methyl-D-erythrose 4-phosphate. It inhibits the E. coli enzyme with a KI value of 38 nM (4), MTB at 80 nM, and the Francisella enzyme at 99 nM. Several mutations in the E. coli DXP reductoisomerase were found to confer resistance to fosmidomycin. ^Wikipedia

Chemistry

SMILES: O=CN(O)CCCP(=O)(O)O
InChIKey: GJXWDTUCERCKIX-UHFFFAOYSA-N
Mol. Mass: 183.1
ALogP: -0.6 Partition coefficient
ChEMBL Molecule:
fosmidomycin

More Chemistry

Pharmacology

Mechanisms of Action:
- 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Escherichia coli) ^UniProt
- 1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic (Plasmodium falciparum (isolate 3D7)) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (11)

Research & Development (11)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Bacterial Infections ()

Malaria (Phase 3)

Malaria, Falciparum (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 11

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue